Orgenesis looks to raise $9.24M in orchestrated private placement

A private placement of 2.2 million shares has been arranged with select investors such as The Phoenix Insurance Company

Orgenesis -
The offering is likely to close on or around January 23

Orgenesis Inc. (NASDAQ:ORGS), a developer of advanced cell therapies, is set to raise roughly $9.24 million on a gross basis in another private placement to finance the expansion of its point-of-care cell-therapy platform. 

Under the deal’s terms, a private placement of 2.2 million shares of the company’s stock has been arranged with select institutional investors, including The Phoenix Insurance Company and Sphera Global Healthcare Master Fund, at a strike price of $4.20 per share.

Additional warrants to purchase up to 1 million shares of Orgenesis stock at an exercise price of $5.50 have also been written. 

READ: Orgenesis adds UC Davis to its point-of-care network for developing cell, gene therapy products

The offering is expected to close on or around January 23, provided closing conditions are met. In addition, the warrants can’t be exercised until six months have passed and they expire three years from their issuance date.

Orgenesis’s point-of-care platform is designed to develop and supply cell and gene products and therapies. With its introduction, hospitals are able to implement Orgenesis’s proprietary automated, closed systems and know-how to collect, process and supply cells for various treatments such as the manufacturing of CAR-T cell therapies.

The Germantown, Maryland-based company provides centralized contract development and manufacturing organization (CDMO) services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland Inc.

Quick facts: Orgenesis

Price: 3.97 USD

Market: NASDAQ
Market Cap: $72.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...



Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read